AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Dr. Reddy's Laboratories Limited

$11.9 -$1.96 (-14.14%)
NYSE · 11 Sep 2026 20:00 UTC
Previous Close
$11.71
Day Range
$11.89$12.03
Year Range
$11.36$15.67
Market Cap
9.91B
AVG Volume
2.67M
Trailing/Forward PE
29.34/0.28
PEG ratio
0.93
Dividend Yield
0.69%
Next Earnings Date
2026-10-23
Primary Exchange
New York Stock ExchangeUS
Revenue (INR) · TTM
0100B200B300B400B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Revenue (INR) · TTM by quarter
PeriodRevenue (INR) · TTM
27 Q1332.83B
26 Q4337.1B
26 Q3345.83B
26 Q2342.15B
26 Q1334.26B
25 Q4325.54B
25 Q3311.31B
25 Q2299.87B
25 Q1220.54B
24 Q4211.19B
Net Income (INR) · TTM
020B40B60B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Net Income (INR) · TTM by quarter
PeriodNet Income (INR) · TTM
27 Q133.17B
26 Q442.88B
26 Q356.59B
26 Q258.62B
26 Q156.8B
25 Q456.54B
25 Q353.68B
25 Q253.33B
25 Q140.96B
24 Q441.06B
Operating Income (INR) · TTM
020B40B60B80B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Operating Income (INR) · TTM by quarter
PeriodOperating Income (INR) · TTM
27 Q135.2B
26 Q449.7B
26 Q366.87B
26 Q271.36B
26 Q171.39B
25 Q471.84B
25 Q369.16B
25 Q267.7B
25 Q150.33B
24 Q450.04B
EBITDA (INR) · TTM
025B50B75B100B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY EBITDA (INR) · TTM by quarter
PeriodEBITDA (INR) · TTM
27 Q155.6B
26 Q477.27B
26 Q393.77B
26 Q298.49B
26 Q198.08B
25 Q495.2B
25 Q390.26B
25 Q288.4B
25 Q164.78B
24 Q464.23B
Cash Flows (INR) · TTM
010B20B30B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Cash Flows (INR) · TTM by quarter
PeriodCash Flows (INR) · TTM
27 Q115.15B
26 Q424.26B
26 Q324.26B
26 Q218.47B
26 Q114.44B
25 Q412.03B
25 Q31.35B
25 Q23.56B
25 Q116.14B
24 Q413.15B
EPS (INR) · TTM
05010015024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY EPS (INR) · TTM by quarter
PeriodEPS (INR) · TTM
27 Q139.8
26 Q451.47
26 Q367.89
26 Q270.31
26 Q168.11
25 Q467.78
25 Q364.35
25 Q263.95
25 Q166.66
24 Q4134.19
Expenses (INR) · TTM
050B100B150B200BR&DSG&ACapex24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Expenses (INR) · TTM by quarter
PeriodExpenses (INR) · TTM
27 Q1160.08B
26 Q4161.16B
26 Q3165.29B
26 Q2164.5B
26 Q1159.91B
25 Q4155.65B
25 Q3140.51B
25 Q2126.75B
25 Q192.8B
24 Q474.64B
Shares Outstanding (INR) · TTM
-500M0500M1B1.5BBuybacks (Repurchases)Stock-Based Compensation24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
RDY Shares Outstanding (INR) · TTM by quarter
PeriodShares Outstanding (INR) · TTM
27 Q1-217M
26 Q4-232M
26 Q31.04B
26 Q2961M
26 Q1954M
25 Q4965M
25 Q3-311M
25 Q2-208M
25 Q1-204M
24 Q4-211M
Dividends (INR)
00.030.050.080.1Jul 19Jul 20Jul 21Jul 22Aug 22Jul 23Jul 23Jul 24Jul 25Jul 26
RDY Dividends (INR) by quarter
PeriodDividends (INR)
Jul 260.08
Jul 250.09
Jul 240.08
Jul 230.1
Jul 230.1
Aug 220.08
Jul 220.08
Jul 210.07
Jul 200.07
Jul 190.06
Employee Count
010K20K30K2017201820192020202120222023202420252026
RDY Employee Count by quarter
PeriodEmployee Count
202627.53K
202527.81K
202427.05K
202325.86K
202224.8K
202122.74K
202021.65K
201921.97K
201823.52K
201722.67K
PE Ratio
15202530med 18.87Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY PE Ratio by quarter
PeriodPE Ratio
Sep 2628.54
Sep 2628.39
Aug 2629.16
Aug 2629.26
Aug 2629.39
Aug 2629.21
Jul 2628.38
Jul 2628.58
Jul 2623.61
Jul 2624.49
Jul 2626.7
Jun 2628.23
Jun 2624.4
Jun 2624.62
Jun 2624.47
May 2625.2
May 2625.33
May 2625.42
May 2618.4
May 2619.17
Apr 2618.96
Apr 2618.13
Apr 2618.24
Apr 2618.24
Mar 2618.81
Mar 2618.97
Mar 2619.24
Mar 2619.49
Feb 2619.27
Feb 2619.35
Feb 2618.84
Feb 2618.77
Jan 2618.11
Jan 2618.46
Jan 2616.63
Jan 2617.16
Jan 2617.7
Dec 2518.04
Dec 2518.02
Dec 2518.02
Dec 2518.11
Nov 2517.81
Nov 2517.69
Nov 2517.54
Nov 2516.93
Oct 2516.74
Oct 2518.17
Oct 2518.62
Oct 2518.64
Oct 2518.4
Sep 2518.46
Sep 2519.18
Sep 2518.95
Sep 2518.51
Aug 2518.33
Aug 2518.67
Aug 2518.33
Aug 2517.78
Aug 2517.92
Jul 2518.69
Jul 2518.38
Jul 2518.34
Jul 2518.98
Jun 2518.97
Jun 2519.43
Jun 2520.05
Jun 2519.65
May 2519.53
May 2519.01
May 2519.18
May 2517.8
May 2518.4
Apr 2518.29
Apr 2518.14
Apr 2517.66
Apr 2516.43
Mar 2517.56
Mar 2518.34
Mar 2517.14
Mar 2517.49
Feb 2517.5
Feb 2518.09
Feb 2518.46
Feb 2519.08
Jan 2518.75
Jan 2518.9
Jan 2520.19
Jan 2520.81
Jan 2520.73
Dec 2421.21
Dec 2420.43
Dec 2419.18
Dec 2419.29
Nov 2418.69
Nov 2424.41
Nov 2424.35
Nov 2425.96
Nov 2425.42
Oct 2426.16
Oct 2427.26
Free Cash Flow Yield
0%1%2%3%med 1.53%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 261.6%
Sep 261.61%
Aug 261.57%
Aug 261.56%
Aug 261.55%
Aug 261.56%
Jul 261.61%
Jul 261.6%
Jul 262.4%
Jul 262.31%
Jul 262.12%
Jun 262%
Jun 262.32%
Jun 262.3%
Jun 262.31%
May 262.24%
May 262.23%
May 262.22%
May 262.33%
May 262.24%
Apr 262.26%
Apr 262.36%
Apr 262.35%
Apr 262.35%
Mar 262.28%
Mar 262.26%
Mar 262.23%
Mar 262.2%
Feb 262.22%
Feb 262.22%
Feb 262.28%
Feb 262.28%
Jan 262.37%
Jan 262.32%
Jan 261.9%
Jan 261.84%
Jan 261.78%
Dec 251.75%
Dec 251.75%
Dec 251.75%
Dec 251.74%
Nov 251.77%
Nov 251.78%
Nov 251.8%
Nov 251.86%
Oct 251.88%
Oct 251.73%
Oct 251.37%
Oct 251.36%
Oct 251.38%
Sep 251.38%
Sep 251.33%
Sep 251.34%
Sep 251.37%
Aug 251.39%
Aug 251.14%
Aug 251.16%
Aug 251.2%
Aug 251.19%
Jul 251.14%
Jul 251.16%
Jul 251.16%
Jul 251.12%
Jun 251.12%
Jun 251.1%
Jun 251.06%
Jun 251.08%
May 250.13%
May 250.13%
May 250.13%
May 250.14%
May 250.14%
Apr 250.14%
Apr 250.14%
Apr 250.14%
Apr 250.15%
Mar 250.14%
Mar 250.14%
Mar 250.15%
Mar 250.14%
Feb 250.38%
Feb 250.37%
Feb 250.36%
Feb 250.35%
Jan 250.36%
Jan 250.35%
Jan 250.33%
Jan 250.32%
Jan 250.32%
Dec 240.31%
Dec 240.33%
Dec 240.35%
Dec 240.35%
Nov 240.36%
Nov 241.61%
Nov 241.62%
Nov 241.52%
Nov 241.55%
Oct 241.51%
Oct 241.45%
Price to Sales
23456med 3.14Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY Price to Sales by quarter
PeriodPrice to Sales
Sep 262.84
Sep 262.83
Aug 262.91
Aug 262.92
Aug 262.93
Aug 262.91
Jul 262.83
Jul 262.85
Jul 263
Jul 263.12
Jul 263.4
Jun 263.59
Jun 263.1
Jun 263.13
Jun 263.11
May 263.21
May 263.22
May 263.23
May 263.01
May 263.14
Apr 263.1
Apr 262.97
Apr 262.98
Apr 262.98
Mar 263.08
Mar 263.1
Mar 263.15
Mar 263.19
Feb 263.15
Feb 263.17
Feb 263.08
Feb 263.07
Jan 262.96
Jan 263.02
Jan 262.85
Jan 262.94
Jan 263.03
Dec 253.09
Dec 253.09
Dec 253.09
Dec 253.1
Nov 253.05
Nov 253.03
Nov 253
Nov 252.9
Oct 252.87
Oct 253.11
Oct 253.16
Oct 253.17
Oct 253.13
Sep 253.14
Sep 253.26
Sep 253.22
Sep 253.15
Aug 253.11
Aug 253.24
Aug 253.18
Aug 253.09
Aug 253.11
Jul 253.25
Jul 253.19
Jul 253.19
Jul 253.3
Jun 253.3
Jun 253.37
Jun 253.48
Jun 253.41
May 253.37
May 253.28
May 253.31
May 253.07
May 253.17
Apr 253.15
Apr 253.13
Apr 253.04
Apr 252.83
Mar 253.03
Mar 253.16
Mar 252.96
Mar 253.02
Feb 253.11
Feb 253.22
Feb 253.28
Feb 253.39
Jan 253.33
Jan 253.36
Jan 253.59
Jan 253.7
Jan 253.69
Dec 243.77
Dec 243.63
Dec 243.41
Dec 243.43
Nov 243.32
Nov 244.53
Nov 244.52
Nov 244.82
Nov 244.72
Oct 244.86
Oct 245.06
EV/EBITDA
81012141618med 11.15Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2616.86
Sep 2616.77
Aug 2617.22
Aug 2617.28
Aug 2617.36
Aug 2617.25
Jul 2616.76
Jul 2616.88
Jul 2612.97
Jul 2613.46
Jul 2614.69
Jun 2615.54
Jun 2613.41
Jun 2613.53
Jun 2613.45
May 2613.86
May 2613.93
May 2613.98
May 2610.95
May 2611.41
Apr 2611.29
Apr 2610.78
Apr 2610.85
Apr 2610.85
Mar 2611.19
Mar 2611.29
Mar 2611.45
Mar 2611.6
Feb 2611.47
Feb 2611.52
Feb 2611.21
Feb 2611.17
Jan 2610.77
Jan 2610.98
Jan 269.78
Jan 2610.1
Jan 2610.42
Dec 2510.62
Dec 2510.61
Dec 2510.61
Dec 2510.66
Nov 2510.49
Nov 2510.41
Nov 2510.32
Nov 259.96
Oct 259.85
Oct 2510.7
Oct 2510.6
Oct 2510.61
Oct 2510.47
Sep 2510.51
Sep 2510.93
Sep 2510.79
Sep 2510.54
Aug 2510.43
Aug 2510.97
Aug 2510.77
Aug 2510.45
Aug 2510.53
Jul 2510.99
Jul 2510.8
Jul 2510.78
Jul 2511.15
Jun 2511.15
Jun 2511.42
Jun 2511.79
Jun 2511.55
May 2511.53
May 2511.22
May 2511.32
May 2510.5
May 2510.85
Apr 2510.79
Apr 2510.7
Apr 2510.41
Apr 259.68
Mar 2510.35
Mar 2510.82
Mar 2510.1
Mar 2510.31
Feb 2510.39
Feb 2510.75
Feb 2510.97
Feb 2511.35
Jan 2511.15
Jan 2511.24
Jan 2512.02
Jan 2512.39
Jan 2512.34
Dec 2412.63
Dec 2412.16
Dec 2411.41
Dec 2411.47
Nov 2411.11
Nov 2414.45
Nov 2414.41
Nov 2415.42
Nov 2415.08
Oct 2415.55
Oct 2416.25
Price/Operating Cashflow
020406080med 22.33Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 2623.09
Sep 2622.97
Aug 2623.59
Aug 2623.67
Aug 2623.78
Aug 2623.63
Jul 2622.96
Jul 2623.12
Jul 2617.91
Jul 2618.57
Jul 2620.25
Jun 2621.41
Jun 2618.51
Jun 2618.67
Jun 2618.56
May 2619.11
May 2619.21
May 2619.28
May 2616.5
May 2617.19
Apr 2617.01
Apr 2616.26
Apr 2616.35
Apr 2616.35
Mar 2616.86
Mar 2617.01
Mar 2617.25
Mar 2617.47
Feb 2617.28
Feb 2617.35
Feb 2616.9
Feb 2616.83
Jan 2616.24
Jan 2616.55
Jan 2616.57
Jan 2617.1
Jan 2617.64
Dec 2517.98
Dec 2517.96
Dec 2517.96
Dec 2518.05
Nov 2517.75
Nov 2517.63
Nov 2517.48
Nov 2516.88
Oct 2516.68
Oct 2518.11
Oct 2520.12
Oct 2520.14
Oct 2519.88
Sep 2519.95
Sep 2520.73
Sep 2520.48
Sep 2520.01
Aug 2519.81
Aug 2522.74
Aug 2522.33
Aug 2521.66
Aug 2521.82
Jul 2522.76
Jul 2522.38
Jul 2522.34
Jul 2523.11
Jun 2523.11
Jun 2523.66
Jun 2524.41
Jun 2523.93
May 2542.68
May 2541.53
May 2541.9
May 2538.89
May 2540.19
Apr 2539.97
Apr 2539.62
Apr 2538.58
Apr 2535.9
Mar 2538.37
Mar 2540.07
Mar 2537.45
Mar 2538.21
Feb 2551.84
Feb 2553.58
Feb 2554.69
Feb 2556.52
Jan 2555.54
Jan 2555.99
Jan 2559.83
Jan 2561.64
Jan 2561.41
Dec 2462.83
Dec 2460.52
Dec 2456.84
Dec 2457.14
Nov 2455.37
Nov 2437.57
Nov 2437.48
Nov 2439.95
Nov 2439.12
Oct 2440.27
Oct 2441.96
Price to Book
22.533.54med 2.95Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
RDY Price to Book by quarter
PeriodPrice to Book
Sep 262.45
Sep 262.43
Aug 262.5
Aug 262.51
Aug 262.52
Aug 262.5
Jul 262.43
Jul 262.45
Jul 262.72
Jul 262.82
Jul 263.07
Jun 263.25
Jun 262.81
Jun 262.83
Jun 262.81
May 262.9
May 262.91
May 262.92
May 262.77
May 262.89
Apr 262.86
Apr 262.73
Apr 262.75
Apr 262.75
Mar 262.83
Mar 262.86
Mar 262.9
Mar 262.93
Feb 262.9
Feb 262.91
Feb 262.84
Feb 262.83
Jan 262.73
Jan 262.78
Jan 262.69
Jan 262.78
Jan 262.87
Dec 252.92
Dec 252.92
Dec 252.92
Dec 252.93
Nov 252.88
Nov 252.86
Nov 252.84
Nov 252.74
Oct 252.71
Oct 252.94
Oct 252.99
Oct 252.99
Oct 252.95
Sep 252.96
Sep 253.08
Sep 253.04
Sep 252.97
Aug 252.94
Aug 253.13
Aug 253.07
Aug 252.98
Aug 253
Jul 253.13
Jul 253.08
Jul 253.08
Jul 253.18
Jun 253.18
Jun 253.26
Jun 253.36
Jun 253.3
May 253.26
May 253.17
May 253.2
May 252.97
May 253.07
Apr 253.05
Apr 253.03
Apr 252.95
Apr 252.74
Mar 252.93
Mar 253.06
Mar 252.86
Mar 252.92
Feb 253.02
Feb 253.12
Feb 253.18
Feb 253.29
Jan 253.23
Jan 253.26
Jan 253.48
Jan 253.59
Jan 253.57
Dec 243.66
Dec 243.52
Dec 243.31
Dec 243.33
Nov 243.22
Nov 243.39
Nov 243.39
Nov 243.61
Nov 243.53
Oct 243.64
Oct 243.79
Dr. Reddy's Laboratories Limited
RDY
Stockpicker

Video analysis: RDY

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: RDY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

prnewswire.com · 10 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

globenewswire.com · 8 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

prnewswire.com · 3 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

globenewswire.com · 1 Sep 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

prnewswire.com · 27 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

globenewswire.com · 25 Aug 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE: RDY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

gurufocus.com · 20 Aug 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

[url="]Glancy Prongay Wolke and Rotter LLP[/url], a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

businesswire.com · 20 Aug 2026

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy's Laboratories (“Dr. Reddy's” or the “Company”) (NYSE: RDY) investors concerning the Company's possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY'S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.What Happ.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.